Diabetes Breakthrough: FDA-Approved Drugs Regenerate Insulin …
A new study shows how pancreatic ductal progenitor cells can be reprogrammed to produce insulin with drugs already used for cancer treatments. The process takes 48 hours and can sense glucose levels, offering a potential alternative to insulin injections for type 1 diabetes.
Breakthrough diabetes study could lead to end of regular insulin ...
Jan 2, 2024 · Researchers from the Baker Heart and Diabetes Institute have found a way to manipulate pancreatic cells to produce insulin using existing cancer drugs. The potential treatment could replace regular insulin injections for people with type 1 and 2 diabetes.
Injection of “smart insulin” regulates blood glucose levels for one ...
Dec 27, 2023 · Researchers at Zhejiang University, China, have developed a glucose-responsive insulin that can be injected once a week and release insulin according to blood-glucose levels. The study tested the...
Glucose-responsive insulin for diabetes | Nature Biotechnology
1 day ago · Using insulin to control diabetes can lead to dangerously low blood glucose levels (hypoglycemia). For many years, researchers have worked to engineer an insulin that avoids this risk by adjusting ...
New medicine can create a new life for diabetes patients
Jan 19, 2024 · Scientists have developed a nano-carrier that protects insulin from stomach acid and delivers it to the liver, where it can lower blood sugar levels. The oral insulin has been tested on baboons...
Harvard diabetes researcher details science behind potential ...
Nov 9, 2021 · Douglas Melton, co-director of Harvard Stem Cell Institute, explains how his lab developed a stem-cell-derived replacement therapy for Type 1 diabetes. The therapy involves transplanting cells that produce insulin into patients, which could change the treatment paradigm.
FDA Approves First Interchangeable Biosimilar Insulin Product …
Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product for diabetes, approved by the FDA in July 2021. It is biosimilar to Lantus (insulin glargine), a long-acting...
For many insulin users, new price cuts will be a 'lifeline' - NBC News
Mar 21, 2023 · After years of public outcry, Novo Nordisk, Eli Lilly and Sanofi announced caps or cuts to the cost of their insulin products. Patients with diabetes said it would make life easier.
An implantable device could enable injection-free control of ... - MIT News
Sep 18, 2023 · MIT engineers developed an implantable device that carries insulin-producing islet cells and generates oxygen by splitting water vapor. The device could keep blood glucose levels stable for at least a month in diabetic mice.
Splitting the chains: ultra-basal insulin analog uncovers a redox ...
2 days ago · A current frontier of insulin pharmacology is defined by the design and clinical application of once-a-week analog formulations 4.Such “ultra-basal” products, which would match the schedule of ...